Clinical Scorecard: Brent Saunders Departs as Bausch + Lomb CEO
At a Glance
| Category | Detail |
|---|---|
| Condition | Bausch + Lomb executive leadership transition |
| Key Mechanisms | Brent Saunders and the board mutually agreed to his departure; Thomas J. Appio was appointed interim CEO, effective immediately. |
| Target Population | Bausch + Lomb employees, customers, patients, and eye care professionals affected by the company’s leadership and operations. |
| Care Setting | Corporate leadership and operations across contact lenses, surgical ophthalmology, pharmaceuticals, and consumer eye care. |
Key Highlights
- Saunders departed less than four years after returning to lead Bausch + Lomb; no further explanation was provided.
- Appio, Bausch Health CEO and Bausch + Lomb board chairman, assumed the interim CEO role while continuing to lead Bausch Health.
- The board cited Appio’s familiarity with the business, international leadership experience, and longstanding relationship with the company.
- Based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA guidance, excluding acquired in-process research and development expenses.
- The companies expected to provide further details with their third-quarter results on Oct. 28.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The article does not report patient-level or prescribing data.
The article describes a corporate leadership change and financial outlook, not clinical treatments or prescribing.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
